Palisade Bio, Inc.
NASDAQ Capital MarketTotal Valuation
Palisade Bio, Inc. carries a market capitalization of 354.10M, placing it among publicly traded companies globally. Its enterprise value stands at -3.16M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 354.10M |
| Enterprise Value | -3.16M |
Share Statistics
Palisade Bio, Inc. currently has 167.62M shares outstanding.
| Shares Outstanding | 167.62M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.81 |
| P/TBV Ratio | 1.02 |
| P/FCF Ratio | -10.44 |
| P/OCF Ratio | -10.44 |
Financial Position
Palisade Bio, Inc. maintains a current ratio of 23.71, meaning it holds 23.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 23.71 |
| Quick Ratio | 23.60 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -2,649.20 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -34.13 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Palisade Bio, Inc.'s stock has gained approximately 177.92916% over the past 52 weeks. The 50-day moving average sits at 1.93, while the 200-day moving average is 1.84.
| Beta (5Y) | N/A |
| 52-Week Price Change | 177.92916% |
| 50-Day Moving Average | 1.93 |
| 200-Day Moving Average | 1.84 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -26.49M, while operating income came in at -26.49M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -26.49M |
| Pretax Income | -24.15M |
| Net Income | -24.15M |
| EBITDA | -26.49M |
| EBIT | -26.49M |
| Earnings Per Share (EPS) | -0.33 |
Balance Sheet
Total book value stands at -160.65M, with working capital of 127.62M providing operational flexibility.
| Cash & Cash Equivalents | 132.63M |
| Total Debt | N/A |
| Net Debt | -132.63M |
| Equity (Book Value) | -160.65M |
| Book Value Per Share | -2.17 |
| Working Capital | 127.62M |
Cash Flow
Palisade Bio, Inc. produced -12.40M in operating cash flow over the past twelve months.
| Operating Cash Flow | -12.40M |
| Capital Expenditures | N/A |
| Free Cash Flow | -12.40M |
| FCF Per Share | -0.17 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -106.46 |
| FCF Yield | -9.58 |
Stock Splits
Palisade Bio, Inc.'s most recent stock split took place on April 8, 2024 with a 15:1 split ratio.
| Last Split Date | 4/8/2024 |
| Split Ratio | 15:1 |
Scores
Palisade Bio, Inc. posts an Altman Z-Score of 11.84, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 11.84 |